MEI Pharma implements 1-for-20 reverse stock split to meet Nasdaq bid price rule

Lite Strategy, Inc.

Board set ratio at 1-for-20; filed Certificate of Amendment with Delaware on April 14, 2023.
Outstanding shares reduced from ~133.3M to ~6.7M; no fractional shares issued, cash in lieu.
Stockholders approved reverse split on Jan 5, 2023; trading starts post-split April 17 under MEIP.
New CUSIP 55279B301; exercise prices of options/warrants proportionally adjusted.
Computershare acting as transfer agent; book-entry holders need no action.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Lite Strategy, Inc.: Filed a Certificate of Amendment to implement a 1-for-20 reverse stock split of common stock, par value $0.00000002 per share (effective 2023-04-14).

Change: charter amendment
Effective: 2023-04-14

Exact text from the filing

On April 14, 2023, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware, to implement the 1-for-20 reverse split of its common stock (the “Reverse Stock Split”).

View on SEC.gov

59 governance changes filed in the last 30 days. Browse all governance changes →

Lite Strategy, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-102213

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.